NB.1.8.1 – COVID-19 Subvariant Explained
NB.1.8.1 is a COVID-19 subvariant of SARS-CoV-2 belonging to the Omicron lineage. Identified in 2025, it carries specific mutations in the spike protein that influence transmissibility and immune evasion.
Things worth knowing about "NB.1.8.1"
NB.1.8.1 is a COVID-19 subvariant of SARS-CoV-2 belonging to the Omicron lineage. Identified in 2025, it carries specific mutations in the spike protein that influence transmissibility and immune evasion.
What is NB.1.8.1?
NB.1.8.1 is a subvariant of SARS-CoV-2, the virus responsible for COVID-19. It belongs to the Omicron lineage and was designated a Variant under Monitoring (VuM) by the World Health Organization (WHO) in 2025. NB.1.8.1 is a descendant of the XEC lineage and carries distinct mutations in the spike protein compared to earlier Omicron subvariants. These mutations influence how the virus binds to human cells and how effectively it can evade immune responses.
Origin and Classification
NB.1.8.1 was first detected at significant levels in Asia, particularly in China and other East Asian countries. The variant emerged through a series of recombination and mutation events within the broader Omicron family. Its designation follows the Pango nomenclature system, which is used globally to systematically classify SARS-CoV-2 lineages.
Mutations and Key Properties
NB.1.8.1 carries several notable mutations in the spike protein, including changes in the receptor-binding domain (RBD). These mutations are associated with the following characteristics:
- Transmissibility: Early data suggest NB.1.8.1 has high transmissibility, comparable to other currently circulating Omicron subvariants.
- Immune evasion: Like many Omicron descendants, NB.1.8.1 can partially evade immunity acquired through vaccination or prior infection.
- Disease severity: Based on available early data, NB.1.8.1 does not appear to cause significantly more severe disease compared to other current Omicron variants.
Symptoms of NB.1.8.1 Infection
Symptoms of infection with NB.1.8.1 are broadly consistent with those seen in other Omicron COVID-19 infections. Common symptoms include:
- Sore throat and hoarseness
- Runny nose and nasal congestion
- Cough (usually dry)
- Headache and general malaise
- Mild fever or chills
- Fatigue and tiredness
Severe illness, such as pneumonia or the need for intensive care, is less common in vaccinated and otherwise healthy individuals but can occur in high-risk groups. These include the elderly, people with underlying health conditions, and those with weakened immune systems.
Diagnosis
Diagnosis of a SARS-CoV-2 infection is still carried out using a PCR test or a rapid antigen test. Specific identification of the NB.1.8.1 variant requires genomic sequencing of viral material, which is performed in specialized laboratories. For routine clinical management, variant identification is generally not required.
Treatment
There is no treatment specifically targeting NB.1.8.1. Management follows general COVID-19 treatment guidelines:
- Mild cases: Symptomatic treatment including rest, adequate fluid intake, and fever-reducing medications as needed.
- Moderate to severe cases: Antiviral drugs such as Nirmatrelvir/Ritonavir (Paxlovid) or Remdesivir may be used in high-risk patients.
- Intensive care: In severe cases, oxygen therapy, mechanical ventilation, and other intensive care measures may be required.
Vaccine Protection and Prevention
Currently approved COVID-19 vaccines, particularly updated mRNA vaccines, continue to provide meaningful protection against severe illness and hospitalization, even if protection against infection with NB.1.8.1 may be reduced due to immune evasion. General preventive measures include:
- Hand hygiene
- Ventilating indoor spaces
- Wearing a respiratory mask in high-risk settings
- Isolating after a positive test result
Global Surveillance
The WHO and national health authorities around the world continuously monitor the spread of NB.1.8.1 and other SARS-CoV-2 variants. The goal is to respond quickly to any changes in transmissibility, disease severity, or vaccine effectiveness. Updated assessments are regularly published on the platforms of the WHO and the European Centre for Disease Prevention and Control (ECDC).
References
- World Health Organization (WHO) - SARS-CoV-2 Variants Tracking, 2025. Available at: https://www.who.int/activities/tracking-SARS-CoV-2-variants
- European Centre for Disease Prevention and Control (ECDC) - SARS-CoV-2 Variants of Concern, 2025. Available at: https://www.ecdc.europa.eu/en/covid-19/variants-concern
- Rambaut A. et al. - A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. Nature Microbiology, 2020. DOI: 10.1038/s41564-020-0770-5
Building Blocks for a Healthy Life
As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.
Verwandte Produkte
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, lactic acid bacteria, and Lactoferrin CLN®
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, lactic acid bacteria, and Lactoferrin CLN®
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.